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Rationale, aims, and objectives: In recent years, several expensive new health tech-
nologies have been introduced. The availability of those technologies intensifies the
discussion regarding the affordability of these technologies at different decision‐mak-
ing levels. On the meso level, both hospitals and clinicians are facing budget con-
straints resulting in a tension to balance between different patients' interests. As
such, it is crucial to make optimal use of the available resources. Different strategies
are in place to deal with this problem, but decisions on a macro level on what to fund
or not can limit the role and freedom of clinicians in their decisions on a micro level. At
the same time, without central guidance regarding such decisions, micro level deci-
sions may lead to inequities and undesirable treatment variation between clinicians
and hospitals. The challenge is to find instruments that can balance both levels of
decision making.
Discussion: Clinicians are becoming increasingly aware that their decisions to spend
more resources (like time and budget) on 1 particular patient group reduce the
resources available to other patients. Involving clinicians in thinking about the optimal
use of limited resources, also in an attempt to bridge the world of economic reasoning
and clinical practice, is crucial therefore. We argue that clinical guidelines may prove a
clear vehicle for this by including both clinical and economic evidence to support the
recommendations made. The development of such guidelines requires cooperation of
clinicians, and health economists are cooperating with each other.
Conclusion: The development of clinical guidelines which combine economic and
clinical evidence should be stimulated, to balance central guidance and uniformity
while maintaining necessary decentralized freedom. This is an opportunity to combine
the reality of budgets and opportunity costs with clinical practice. Missing this oppor-
tunity risks either variation and inequity or central and necessarily crude measures.
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562 KNIES ET AL.1 | INTRODUCTION
The affordability of new health technologies, amongst which
expensive pharmaceuticals, remains an important issue at different
decision‐making levels in health care. In addition to national deci-
sion makers (mostly involved in reimbursement decisions), also
hospitals and clinicians are directly or indirectly faced with budget-
ary constraints. As a result, also hospitals and clinicians struggle to
balance budget constraints with their patients' interests. Finding
this balance is extremely difficult at any level and is high on the
political agenda in many countries. Failure to make such choices
at a national level and to provide adequate financing of new tech-
nologies leads to pressure, choices, and potentially inequities at
lower levels of the health care system. This is also true for positive
reimbursement decisions at a central level, which may lead to pressure
on existing budgets if these do not grow to cover the related (net)
expenses.1
This tension between all patients' needs and available budget
reflects the classical issue that health care systems simply do not
have enough resources to provide all patients with every available
(potentially) effective clinical intervention.2,3 Because the tension
between budgetary constraints and patients' demands and needs
is unavoidable, it is crucial to make optimal use of the available
resources. Countries use different strategies in this context, includ-
ing decision making based on health technology assessments, price
negotiations, and restricting access to expensive pharmaceuticals.4
Macro level decisions may give financial access and stimulate
equity, but they can also be relatively crude as they tend to make
technologies accessible to either all patients, some selection of
patients, or none. This does not do justice to the often encountered
variation within patient populations and treatment effects, which
clinicians observe at the micro level. Surprisingly, these clinicians
are not always involved in macro decisions which does not do jus-
tice to their important role. On the meso level, clinicians are typi-
cally part of the struggle to balance limited resources and
individual patients' interests for instance in budget allocations over
different specialities. These choices have implications for the tech-
nologies offered to patients and may vary between hospitals. Leav-
ing the difficult decisions regarding what to fund or reimburse and
for whom up to individual clinicians for each individual patient, or
on a micro level, could lead to further inequities and undesirable
reatment variation. The challenge is therefore to find a golden mid-
dle to balance uniformity at a central level and flexibility at the
micro level.
It seems that this search is still ongoing. Clinicians increasingly
feel the pressure of limited available resources, whether or not
they are responsible for budgets themselves. They appear to be
well aware of the fact that their decisions have an impact on the
resources available to other patients. Hence, clinicians may con-
sider whether their health care organization, health care system
(especially mandatory tax or insurance financed ones), or even soci-
ety as a whole can afford specific technologies.5 Involving clinicians
in thinking about the optimal use of limited resources, also in an
attempt to bridge the world of budgets and clinical practice, is cru-
cial therefore.2 | DISCUSSION
2.1 | Need for efficient guidelines
Evidence‐based clinical guidelines, for which a rising interest can be
noticed, may well prove the best instrument to link the macro and
micro level. These guidelines are developed, often by medical profes-
sionals associations, as a tool to inform clinicians about the current
state of knowledge regarding the benefits and limitations of specific
technologies for defined health problems.6,7 The increasing complexity
of health technologies, a growing desire to increase quality of care and
reduce variation, and the necessity to control costs, has led to the
growing use of clinical guidelines in the last 3 decades.8 Guidelines
may thus be used as a means for internal quality assurance by optimiz-
ing the actions of individual clinicians, whereby it is important to note
that quality is a multidimensional concept.7 For instance, the World
Health Organization distinguishes 6 dimensions of quality, being:
effectiveness, efficiency, accessibility, acceptability/patient‐centered,
equity, and safety.9 Clinical guidelines can contribute to improve qual-
ity of care in different ways, but it can be argued that not all aspects of
quality are equally relevant in the context of guidelines.7,10 In general,
clinical guidelines try to inform clinicians about the potential effective-
ness and safety of a specific technology for a defined health problem.
Until now, the majority of clinical guidelines have paid limited atten-
tion on efficiency of care as a dimension of quality.7
Critical questions can be raised on whether clinicians have to deal
with economic arguments in individual patient decisions or whether
clinical guidelines should incorporate economic arguments. Dutch find-
ings indicate that clinicians think that it is possible to take cost‐effec-
tiveness data into account in clinical practice; however, they do not
want to make the decision in their consulting room without further
guidance (and backing). Incorporating cost‐effectiveness data in clinical
guidelines is therefore considered as the way forward.11 This accords
with the message of optimizing the allocation of scarce health care
resources by informing decisions using economic evidence, as health
economists try to bring across. In order to do so, all other things
equal, health care systems could prioritize technologies that result in
the highest health gain per monetary unit spent. In appraising these
technologies, other aspects (and health system goals) like equity can
be included as well. But by prioritizing clinical practices that are the
most cost‐effective, guidelines can help in the pursuit of optimizing
population health from a given budget. As clinical guidelines aim to
advice on which treatments to give under which circumstances, guide-
lines are very suitable for promoting cost‐effective clinical practice on
a level of detail that is not encountered in normal central reimburse-
ment decisions.3 Such practice acknowledges that health technologies
are not effective or cost‐effective per se, but only in the appropriate
target group and circumstances.
Ignoring economic evidence when developing clinical guidelines
could result in treatment recommendations that do not represent a
cost‐effective use of health technologies and may therefore ultimately
be harmful for the use of other technologies, patients, and population
health. Moreover, failure to address this pressing matter through the
here proposed route results in decisions being made at other levels,
given that resources remain too scarce to treat all patients to the best
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or varying between hospitals (meso level) or clinicians (micro level).
Without considering economic evidence, guidelines may add to the
tension between available recourses on the one hand, and treatment
options and patients demands on the other. Ideally, guidelines indicate
how to offer optimal care taking the available resources into consider-
ation, by incorporating cost‐effectiveness data in the recommenda-
tions stated in clinical guidelines.12 Guidelines could in this way
increase quality of care and ensure an efficient allocation of resources
at the same time.7,82.2 | Experience in England and the Netherlands
Is there any evidence that this can work? Both England and Wales and
the Netherlands have some positive experience including economic evi-
dence in clinical guidelines. In England and Wales, cost‐effectiveness is
considered at every stage of the development process of new clinical
guidelines. The development of a guideline starts with the development
of the scope. Next, the guideline itself is development in which a sys-
tematic literature review is conducted and, if necessary, additional
cost‐effectiveness studies are performed. Third, the recommendations
are developed for each topic in the guideline based on the earlier col-
lected clinical and economic evidence. Finally, the guideline is drafted,
and a consultation follows by asking stakeholders their opinion, after
which the guideline is implemented.3 A problem arises when limited
clinical evidence is available, but with substantial cost differences exist.
In this case, the choice has to be made what option to recommend.3
From experience in the Netherlands, we can learn that it is important
to understand the viewpoint from various professions, and the comple-
mentarity in the overall aim of improving population health. In addition,
the members and (especially) the chair of the guideline development
group should be convinced of the added value of incorporating health
economic evidence.13 The role of clinicians in this process of incorporat-
ing cost‐effectiveness data in their guidelines is crucial as their clinical
knowledge has to be combined with economic arguments.
The experience from the Netherlands and England andWales shows
that combining clinical and economic evidence is possible, but that it is
important to consider economic evidence in every stage of developing
clinical guidelines. Such guidelines stimulate cost‐effective care by limit-
ing the use of health technologies to those situations in which they
can be considered to offer value for money. The focus on the value of
the care delivered is in line with recent developments towards value‐
based health care. One of the steps taken to influence health care pro-
viders in improving the value of health care is to create guidelines iden-
tifying best practices and value for money.14 Putting limitations on the
use of health technologies using economic evidence is not based on
the wish to save money but to be able to create more value: save more
lives, improve quality of life, and further improve overall population
health using the available resources as efficiently as possible.3 | CONCLUSION
Developing guidelines based on clinical evidence, incorporating
economic data is impossible without an intensive collaborationbetween clinicians and health economists. Crude choices and unde-
sirable treatment variation may be avoided by, next to clinical evi-
dence consistently including economic evidence in clinical
guidelines. Ideally, national decision‐making bodies set the bound-
aries and principles for developing such clinical guidelines, after
which clinicians specify the guidance with inputs from health econ-
omists. Next to that, sufficient resources should be available to be
able to implement the recommendations in guidelines in daily prac-
tice. In other words, the financial streams need to enable the actors
to provide the care that society deems necessary, effective, and
cost‐effective.
While clinicians may see cost‐effectiveness as something alien,
threatening rather than improving health, the opposite may be true.
Joining forces allows for tailor‐made, patient centered, and cost‐effec-
tive clinical guidelines, contributing to population health: joint input
from both professions is more needed than ever!
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